IL308811A - Neodegrader conjugates - Google Patents
Neodegrader conjugatesInfo
- Publication number
- IL308811A IL308811A IL308811A IL30881123A IL308811A IL 308811 A IL308811 A IL 308811A IL 308811 A IL308811 A IL 308811A IL 30881123 A IL30881123 A IL 30881123A IL 308811 A IL308811 A IL 308811A
- Authority
- IL
- Israel
- Prior art keywords
- neodegrader
- conjugates
- neodegrader conjugates
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6867—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of a blood cancer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163202273P | 2021-06-03 | 2021-06-03 | |
US202163282585P | 2021-11-23 | 2021-11-23 | |
PCT/IB2022/055167 WO2022254376A1 (en) | 2021-06-03 | 2022-06-02 | Neodegrader conjugates |
Publications (1)
Publication Number | Publication Date |
---|---|
IL308811A true IL308811A (en) | 2024-01-01 |
Family
ID=84323936
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL308811A IL308811A (en) | 2021-06-03 | 2022-06-02 | Neodegrader conjugates |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP4346909A1 (en) |
JP (1) | JP2024521921A (en) |
KR (1) | KR20240040067A (en) |
AU (1) | AU2022287316A1 (en) |
CA (1) | CA3222182A1 (en) |
CL (1) | CL2023003604A1 (en) |
CO (1) | CO2023016711A2 (en) |
IL (1) | IL308811A (en) |
TW (1) | TW202313124A (en) |
WO (1) | WO2022254376A1 (en) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2527952C2 (en) * | 2008-10-29 | 2014-09-10 | Селджин Корпорейшн | Isoindoline compounds used for treating cancer |
EP4126067A1 (en) * | 2020-03-31 | 2023-02-08 | Orum Therapeutics Inc. | Neodegrader conjugates |
-
2022
- 2022-06-02 CA CA3222182A patent/CA3222182A1/en active Pending
- 2022-06-02 IL IL308811A patent/IL308811A/en unknown
- 2022-06-02 JP JP2023574590A patent/JP2024521921A/en active Pending
- 2022-06-02 AU AU2022287316A patent/AU2022287316A1/en active Pending
- 2022-06-02 WO PCT/IB2022/055167 patent/WO2022254376A1/en active Application Filing
- 2022-06-02 EP EP22815473.8A patent/EP4346909A1/en active Pending
- 2022-06-02 TW TW111120734A patent/TW202313124A/en unknown
- 2022-06-02 KR KR1020247000099A patent/KR20240040067A/en unknown
-
2023
- 2023-12-01 CL CL2023003604A patent/CL2023003604A1/en unknown
- 2023-12-01 CO CONC2023/0016711A patent/CO2023016711A2/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU2022287316A1 (en) | 2023-12-14 |
KR20240040067A (en) | 2024-03-27 |
AU2022287316A9 (en) | 2024-01-04 |
TW202313124A (en) | 2023-04-01 |
CO2023016711A2 (en) | 2024-02-26 |
WO2022254376A1 (en) | 2022-12-08 |
CA3222182A1 (en) | 2022-12-08 |
CL2023003604A1 (en) | 2024-05-03 |
JP2024521921A (en) | 2024-06-04 |
EP4346909A1 (en) | 2024-04-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL286291A (en) | Compounds and conjugates thereof | |
CA196956S (en) | Onesie | |
IL291486A (en) | Therapeutic conjugates | |
CA199411S (en) | Handshower | |
GB201820626D0 (en) | Conjugates | |
IL308812A (en) | Neodegrader-anti-cd33 antibody conjugates | |
GB2594753B (en) | Antibody-drug conjugates | |
CA198107S (en) | Protractor-ruler | |
GB201820864D0 (en) | Antibody-drug conjugates | |
GB201917699D0 (en) | Vaccine conjugates | |
IL308811A (en) | Neodegrader conjugates | |
GB202210058D0 (en) | Conjugates | |
IL288681A (en) | Pyrrolobenzodiazepine-antibody conjugates | |
IL307947A (en) | Protein-antiviral compound conjugates | |
GB201906997D0 (en) | Conjugates | |
GB201900735D0 (en) | Conjugates | |
CA201360S (en) | Débardeur | |
CA200872S (en) | Nighstand | |
CA200597S (en) | Hoodie | |
CA200456S (en) | Hoodie | |
CA200353S (en) | Balaclava | |
CA196479S (en) | Protractor-ruler | |
GB202000121D0 (en) | Compounds and conjugates | |
GB202105187D0 (en) | Pyrrolobenzodiazepine conjugates | |
GB202105186D0 (en) | Pyrrolobenzodiazepine conjugates |